EG-1962

EG-1962 is a sustained-release microparticle formulation of nimodipine, a dihydropyridine calcium channel blocker, developed for the treatment of aneurysmal subarachnoid hemorrhage (aSAH). It was designed by Edge Therapeutics to be administered directly into the brain's ventricles, providing high local concentrations of the drug to prevent delayed cerebral ischemia while avoiding the systemic side effects, such as hypotension, associated with oral nimodipine. The formulation utilizes technology licensed from Evonik and was manufactured in collaboration with Oakwood Laboratories. In March 2018, Edge Therapeutics discontinued the Phase 3 NEWTON 2 study following an interim analysis which indicated a low probability of the trial meeting its primary endpoint. Subsequently, Edge Therapeutics underwent a reverse merger with PDS Biotechnology in 2019.

Other names

nimodipine microparticlessustained-release nimodipine